Ketamine as the prototype glutamatergic antidepressant: Pharmacodynamic actions, and a systematic review and meta-analysis of efficacy

Therapeutic Advances in Psychopharmacology

Volumn 4, Issue 2, 2014, Pages 75-99

  Caddy, Caroline ^a   Giaroli, Giovanni ^a   White, Thomas P ^a   Shergill, Sukhwinder S ^a   Tracy, Derek K ^b,c  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antidepressant; glutamatergic; ketamine

Indexed keywords

EID: 84998013997     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313507739     Document Type: Review

References (99)

1. aan het Rot M. Collins K. Murrough J. Perez A. Reich D. Charney D. et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67: 139–145.
2. Abdallah C. Fasula M. Kelmendi B. Sanacora G. Ostroff R. (2012) Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT 28: 157–161.
3. Abe H. Rusak B. Robertson H. (1992) NMDA and non-NMDA receptor antagonists inhibit photic induction of Fos protein in the hamster suprachiasmatic nucleus. Brain Res Bull 28: 831–835.
4. Albayrak Y. Hashimoto K. (2012) Beneficial effects of sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases. Prim Care Companion CND Disord 14: PCC.12br01401.
5. Autry A. Adachi M. Nosyreva E. Na E. Los M. Cheng P. et al. (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91–95.
6. Baune B. Adrian I. Jacobi F. (2007) Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. J Psychosom Res 62: 109–118.
7. Bellet M. Vawter M. Bunney B. Bunnet W. Sassone-Corsi P. (2011) Ketamine influenced CLOCK:BMAL1 function leading to altered circadian gene expression. PLoS One 6: e23982.
8. Berman R. Cappiello A. Anand A. Oren D. Heninger G. Charney D. et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351–354.
9. Beurel E. Song L. Jope R. (2011) Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 16: 1068–1070.
10. Brown K. Tracy D. (2013) Lithium: the pharmacodynamics actions of the amazing ion. Ther Adv Psychopharmacol 3: 163–176.
11. Carpenter R. Falkenburg J. White T. Tracy D. (2013) Crisis teams: systematic review of their effectiveness in practice. Psychiatrist 37: 232–237.
12. Carr D.B. Goudas L.C. Denman W.T. Brookoff D. Lavin P.T. Staats P.S. (2004) Safety and efficacy of intranasal ketamine in a mixed population with chronic pain. Pain 110: 762–764.
13. Colwell C. Menaker M. (1992) NMDA as well as non-NMDA receptor antagonists can prevent the phase-shifting effects of light on the circadian system of the golden hamster. J Biol Rhythms 7: 125–136.
14. Craven R. (2007) Ketamine. Anaesthesia 62: S48–53.
15. Davis L. Frazier E. Gaynes B. Trivedi M. Wisniewski S. Fava M. et al. (2007) Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. J Clin Psychiatry 68: 1931–1938.
16. De Berardis D. Marini S. Fornaro M. Srinivasan V. Iasevoli F. Tomasetti C. et al. (2013) The melantonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. Int J Mol Sci 14: 12458–12483.
17. DiazGranados N. Ibrahim L. Brutsche N. Ameli R. Henter I. Luckenbaugh D. et al. (2010a) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychol 71: 1605–1611.
18. DiazGranados N. Ibrahim L. Brutsche N. Newberg A. Kronstein P. Khalife S. et al. (2010b) Randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment resistant bipolar depression. Arch Gen Psychiatry 67: 793–802.
19. Du J. Suzuki K. Wei Y. Wang Y. Blumenthal R. Chen Z. et al. (2007) The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32: 793–802.
20. Duman R. (2004) Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med 5: 11–25.
21. Duman R. Voleti B. (2012) Signalling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid acting agents. Trends Neurosci 35: 47–56.
22. Duncan W. Sarasso S. Ferrarelli F. Selter J. Riedner B. Hejazi N. et al. (2012) Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Intl J Neuropsychopharmacol 16: 301–311.
23. Entsuah A.R. Huang H. Thase M.E. (2001) Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 62: 869–77.
24. Glue P. Gulati A. Le Nedelec M. Duffull S. (2011) Dose- and exposure-response to ketamine in depression. Biol Psychiatry 70: e9–10.
25. Goforth H.W. Holsinger T. (2007) Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT 23: 23–5.
26. Grant B. Stinson F. Hasin D. Dawson D. Chou S. Ruan W. et al. (2005) Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychol 66: 1205–1215.
27. Grassi-Zucconi G. Semprevivo M. Mocaer E. Kristensson K. Bentivoglio M. (1996) Melatonin and its new agonist S-20098 restore synchronised sleep fragmented by experimental trypanosome infection in the rat. Brain Res Bull 39: 63–68.
28. Guo M. Lu Y. Garza J. Li Y. Chua S. Zhang W. et al. (2012) Forebrain glutamatergic neurons mediate leptin action on depression-like behaviours and synaptic depression. Translational Psychiatry 2: e83.
29. Hamilton J. Furman D. Chang C. Thomason M. Dennis E. Gotlib I. (2011) Default-mode and task-positive network activity in major depressive disorder: Implications for adaptive and maladaptive rumination. Biol Psychiatry 70: 327–333.
30. Hayashi T. Su T. (2008) An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. Exp Opin Ther Targets 12: 45–58.
31. Hayashi T. Tsai S. Mori T. Fujimoto M. Su T. (2011) Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Exp Opin Ther Drugs 15: 557–577.
32. Ibrahim L. DiazGranados N. Luckenbaugh D. Machado-Vieira R. Baumann J. Mallinger A. et al. (2011) Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35: 1155–1159.
33. Ibrahim L. DiazGranados N. Franco-Chavos J. Brutsche N. Henter I. Kronstein P. et al. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37: 1526–1533.
34. Ishima T. Hashimoto K. (2012) Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil; the role of sigma-1 and IP3 receptors. PLoS One 7: e37989.
35. Jernigan C. Goswami D. Austin M. Iyo A. Chandran A. Stockmeier C. et al. (2011) The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuro-Psychopharmacology Biol Psychiatry 35: 1774 –1779.
36. Kessler R. Akiskal H. Ames M. Birnbaum H. Greenberg P. Hirschfeld R. et al. (2006) Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 163(9); 1561–1568.
37. Kessler R. Berglund P. Demler O. Jin R. Koretz D. Merkangas K. et al. (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 289: 3095–3105.
38. Kinsler R. Dunman R. (2008) Acute ketamine administration increases VEGF expression in the hippocampus: potential role in the rapid antidepressant effects of ketamine. In: Society for Neuroscience Meeting, Washington, DC, 2003, Abstract #56.14.
39. Kishimoto A. Kaneko M. Gotoh Y. Hashimoto K. (2012) Ifenprodil for the treatment of flashbacks in female posttraumatic stress disorder patients with a history of childhood sexual abuse. Biol Psychiatry 71: e7-e8.
40. Kishimoto A. Yatomi K. Yokoyama Y. Nakatsu N. Fujita K. Hashimoto K. (2013) Ifenprodil for emotional incontinence in patients with vascular dementia. J Clin Psychopharmacol 33: 143–145.
41. Kranaster L. Kammerer-Ciernioch J. Hoyer C. Sartorius A. (2011) Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study. Eur Arch Psychiatry Clin Neurosci 261: 575–582.
42. Krystal J. Karper L. Seibyl J. Freeman G. Delaney R. Bremmer D. et al. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51: 199–214.
43. Krystal J.H. Sanacora G. Duman R.S. (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73: 1133–41.
44. Kudoh A. Takahira Y. Katagai H. Takazawa T. (2002) Small-dose ketamine improves the postoperative state of depressed patients. Anesthesia Analgesia 95: 114–118.
45. Larkin G. Beautrais A. (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14: 1127–1131.
46. Li N. Lee B. Liu R. Bansr M. Dwyer J. Iwata M. et al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959–964.
47. Liu J. Garza J. Bronner J. Kim C. Zhang W. Lu X. (2010) Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology 207: 535–545.
48. Lloyd L. Giaroli G. Taylor D Tracy D. (2011) Bipolar depression: clinically missed, pharmacologically mismanaged. Ther Adv Psychopharmacol 1: 153–162.
49. Loo C. Katalinic N. Garfield J. Sainsbury K. Hadzi-Pavlovic D. MacPherson R. (2012) Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord 142: 233–240.
50. Lord B. Wintmolders C. Langlois X. Nguyen L. Lovenberg T. Bonaventure P. (2013) Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus. Eur J Pharmacol, in press. DOI: 10.1016/j.ejphar.2013.06.028.
51. Lu X. Kim C. Frazer A. Zhang W. (2006) Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 103: 1593–1598.
52. Luppino F. de Wit L. Bouvy P. Stijnen T. Cuijpers P. Penninx B. et al. (2010) Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 67: 220–229.
53. Ma X. Dang Y. Jia M. Ma R. Wang F. Wu J. et al. (2013) Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 8: e56053.
54. Machado-Vieira R. Salvadore G. Luckenbaugh D. Manji H. Zarate C. (2009) Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychology 69: 946–958.
55. MacPherson R. Loo C. (2008) Cognitive impairment following electroconvulsive therapy-does the choice of anesthetic agent make a difference? J ECT 24: 52–56.
56. Maeng S. Zarate C. Du J. Schloesser R. McCammon J. Chen G. et al. (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydorxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349–352.
57. Mathew S. Murrough J. aan het Rot M. Collins K. Reich D. Charney D. (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13: 71–82.
58. Merikangas K. Akiskal H. Angst J. Greenberg P. Hirschfeld R. Petukhova M. et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64: 543552.
59. Moghaddam B. Krystal J. (2012) Capturing the angel in “angel dust”: Twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophrenia Bull 38: 942–949.
60. Murrough J. Perez A. Pillemer S. Stern J. Parides M. aan het Rot M. et al. (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry, in press.
61. Nichols D. (2004) Hallucinogens. Pharmacol Therapeutics 101: 131–181.
62. Nishimura T. Ishima T. Iyo M. Hashimoto K. (2008) Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signalling pathways. PLoS One 3: e2558.
63. Okamoto N. Nakai T. Sakamoto K. Nagafusa Y. Higuchi T. Nishikawa T. (2010) Rapid antidepressant effect of ketamine anaesthesia during electroconvulsive therapy of treatment-resistant depression. J ECT 26: 223–227.
64. Pal A. Fontanilla D. Gopalakrishnan A. Chae Y. Markley J. Ruoho A. (2012) The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol 5: 1–3.
65. Papanastasiou E. Stone J. Shergill S. (2013) When the drugs don't work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry 202: 91–93.
66. Penn E. Tracy D. (2012) The drugs don't work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2: 179–188.
67. Petrakis I. Limoncelli D. Gueorguieva R. Jatlow P. Boutros N. Trevisan L. et al. (2004) Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry 161: 1776–1782.
68. Phelps L. Brutsche N. Moral J. Luckenbaugh D. Manki H. Zarate C. (2009) Family history of alcohol dependence and initial antidepressant response to an NMDA antagonist. Biol Psychiatry 65: 181–184.
69. Poleszak E. Wośko Serefko A. Szopa A. Wlaź A. Szewczyk B. Nowak G. et al. (2013) Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 46: 29–35.
70. Pompili M. Serafina G. Innamorati M. Venturini P. Fusar-Poli P. Sher L. et al. (2013) Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry, in press. DOI: 10.3109/15622975.2013.765593.
71. Popoli M. Yan Z. McEwen B. Sanacora G. (2012) The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13: 22–37.
72. Preskorn S. Baker B. Kolluri S. Menniti F. Krams M. Landen J. (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28: 631–637.
73. Price R. Nock M. Charney D. Mathew S. (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66: 522–526.
74. Raichle M. MacLeod A. Snyder A. Powers W. Gusnard D. Shulman G. (2001) A default mode of brain function. Proc Natl Acad Sci USA 98: 676–682.
75. Rasmussen K. Lineberry T. Galardy C. Kung S. Lapid M. Palmer B. et al. (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27: 444–450.
76. Salvadore G. Cornwell B. Colon-Roasario V. Coppola R. Grillon C. Zarate C. et al. (2009) Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65: 289–295.
77. Salvadore G. Cornwell B. Sambataro F. Latov D. Colon-Rosario V. Carver F. et al. (2010) Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35: 1415–1422.
78. Salvadore G. van der Veen J. Zhang Y. Marenco S. Machado-Vieira R. Baumann J. et al. (2012) An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol 15: 1063–1072.
79. Sanacora G. Treccani G. Popoli M. (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders Neuropharmacology 62: 63–77.
80. Scheidegger M. Walter M. Lehmann M. Metzger C. Grimm S. Heinz B. et al. (2012) Ketamine decreases restung state functional network connectivity in healthy subjects: Implications for antidepressant action. PloS One 7: e44799.
81. Sen S. Duman R. Sanacora G. (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64: 527–532.
82. Sendt K. Giaroli G. Tracy D. (2012) Beyond dopamine: glutamate as a target for future antipsychotics. ISRN Pharmacol. DOI: 10.5402/2012/427267.
83. Sheline Y. Price J. Yan Z. Mintun M. (2010) Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci 107: 11020–11025.
84. Shimizu E. Hashimoto K. Okamura N. Koike K. Komatsu N. Kumakiri C. et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70–75.
85. Stahl S. (2008) The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 69: 1673–1634.
86. Stern R. Schmeidler J. Davidson M. (1997) Limitations of controlled augmentation trails in schizophrenia. Biol Psychiatry 42: 138–143.
87. Taylor V. MacQueen G. (2010) The role of adipokines in understanding the associations between obesity and depression. J Obesity. DOI: 10.1155/2010/748048.
88. Thase M.E. Haight B.R. Richard N. Rockett C.B. Mitton M. Modell J.G. et al. (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomised controlled trials. J Clin Psychiatry 66: 974–81.
89. Tracy D. Sendt K. Shergill S. (2013) Antipsychotic polypharmacy: still dirty, hardly a secret. A systematic review and clinical guide. Curr Psychopharmacol 2: 1–29.
90. Tracy D. Shergill S. (2013) Mechanisms underlying auditory hallucinations – understanding perception without stimulus. Brain Sci 3: 642–669.
91. Valentine G. Mason G. Gomex R. Fasula M. Watzl J. Pittman B. et al. (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res 191: 122–127.
92. Wang C. Zheng D. Xu J. Lam W. Yew D. (2013) Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat 7: 23.
93. Wang X. Chen Y. Zhou X. Liu F. Zhang T. Zhang C. (2012) Effects of propofol and ketamine as combined anaesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT 28: 128–132.
94. Wozniak S. Gee L. Wachtel M. Frezza E. (2009) Adipose tissue: the new endocrine organ? A review article. Digest Dis Sci 54: 1847–1856.
95. Yamada N. Katsuura G. Ochi Y. Ebihara K. Kusakabe T. Hosoda K. et al. (2011) Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 152: 2634–2643.
96. Yang C. Hu Y. Zhou Z. Zhang G. Yang J. (2013) Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Upsala J Med Sci 118: 3–8.
97. Zarate C. Brutsche N. Ibrahim L. Franco-Chaves J. DiazGranados N. Cravchik A. et al. (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71: 939–946.
98. Zarate C. Singh J. Carlson P. Brutsche N. Ameli B. Luckenbaugh D. et al. (2006) A randomized trials of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856–864.
99. Zhang C. Feng Z. Liu Y. Ji X. Peng J. Zhang X. et al. (2012) Methylphenidate enhances NMDA-receptor response in medial prefrontal cortex via sigma-1 receptor: a novel mechanism for methylphenidate action. PLoS One 7: e51910.